Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate-to-Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial
JAMA Dermatol 2022 Apr 13;[EPub Ahead of Print], AS Paller, MMB Seyger, GA Magariños, A Pinter, JC Cather, C Rodriguez-Capriles, D Zhu, N Somani, A Garrelts, KA PappFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.